Alpha 2.0
Login Register
» Authors » Johan Vansteenkiste

Johan Vansteenkiste

Explore the profile of Johan Vansteenkiste including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 176
Citations 18400
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Pharmacology
Top 10 Co-Authors
Christophe Dooms
Paul De Leyn
Eric Verbeken
Dirk De Ruysscher
Kristiaan Nackaerts
Herbert Decaluwe
Els Wauters
Isabelle Wauters
Keunchil Park
Walter De Wever
Published In
J Thorac Oncol
Lung Cancer
J Clin Oncol
Eur J Cancer
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Wolf J, Hochmair M, Han J, Reguart N, Souquet P, Smit E, et al.
Lancet Oncol . 2024 Oct; 25(10):1357-1370. PMID: 39362249
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes...
2.
Treatment of unresectable stage III NSCLC: Real world cohort study and literature review
Verfaillie S, Lambrecht M, Berkovic P, Dooms C, Nackaerts K, Van de Velde A, et al.
Cancer Treat Res Commun . 2023 Jun; 36:100727. PMID: 37307680
Introduction: Until recently, the treatment for patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC) was combined chemoradiotherapy (CRT), delivered either concurrently (cCRT) or sequentially (sCRT). There...
3.
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer
Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al.
J Clin Oncol . 2023 May; 41(14):2458-2466. PMID: 37146426
Purpose: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in...
4.
Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors
Tohidinezhad F, Bontempi D, Zhang Z, Dingemans A, Aerts J, Bootsma G, et al.
Eur J Cancer . 2023 Mar; 183:142-151. PMID: 36857819
Introduction: Immunotherapy-induced pneumonitis (IIP) is a serious side-effect which requires accurate diagnosis and management with high-dose corticosteroids. The differential diagnosis between IIP and other types of pneumonitis (OTP) remains challenging...
5.
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al.
J Clin Oncol . 2023 Feb; 41(6):1162-1171. PMID: 36791474
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated...
6.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
Cheema P, Cho B, Freitas H, Provencio M, Chen Y, Kim S, et al.
Future Oncol . 2023 Jan; 19(1):61-75. PMID: 36656302
Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC). Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI...
7.
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Franken A, Van Mol P, Vanmassenhove S, Donders E, Schepers R, Van Brussel T, et al.
J Immunother Cancer . 2022 Sep; 10(9). PMID: 36171010
Background: Immune checkpoint inhibitor (ICI)-related pneumonitis is the most frequent fatal immune-related adverse event associated with programmed cell death protein-1/programmed death ligand-1 blockade. The pathophysiology however remains largely unknown, owing...
8.
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer
Sibille A, Bustin F, Carestia L, Catala G, Compere C, Cuppens K, et al.
Acta Oncol . 2022 May; 61(6):773-776. PMID: 35574825
No abstract available.
9.
Value of [Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
Deleu A, Laenen A, Decaluwe H, Weynand B, Dooms C, De Wever W, et al.
EJNMMI Res . 2022 May; 12(1):28. PMID: 35524900
Background: Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited number of studies...
10.
Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer
Claerhout S, Lehnert S, Vander Borght S, Spans L, Dooms C, Wauters E, et al.
Lung Cancer . 2022 Apr; 166:242-249. PMID: 35378489
Objectives: Targeted RNA-based Next-Generation Sequencing (tRNA-seq) is increasingly being used in molecular diagnostics for gene fusion detection in non-small cell lung cancer (NSCLC). However, few data support its clinical application...